These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Vascular effects of ketanserin (R 41 468), a novel antagonist of 5-HT2 serotonergic receptors. Van Nueten JM; Janssen PA; Van Beek J; Xhonneux R; Verbeuren TJ; Vanhoutte PM J Pharmacol Exp Ther; 1981 Jul; 218(1):217-30. PubMed ID: 6113280 [TBL] [Abstract][Full Text] [Related]
3. LY215840, a potent 5-hydroxytryptamine (5-HT)2 receptor antagonist, blocks vascular and platelet 5-HT2 receptors and delays occlusion in a rabbit model of thrombosis. Cohen ML; Robertson DW; Bloomquist WE; Wilson HC J Pharmacol Exp Ther; 1992 Apr; 261(1):202-8. PubMed ID: 1560366 [TBL] [Abstract][Full Text] [Related]
4. Antihypertensive properties of ketanserin (R 41 468). Vanhoutte PM; Van Nueten JM; Symoens J; Janssen PA Fed Proc; 1983 Feb; 42(2):182-5. PubMed ID: 6295821 [TBL] [Abstract][Full Text] [Related]
14. LY53857, a selective and potent serotonergic (5-HT2) receptor antagonist, does not lower blood pressure in the spontaneously hypertensive rat. Cohen ML; Fuller RW; Kurz KD J Pharmacol Exp Ther; 1983 Nov; 227(2):327-32. PubMed ID: 6313898 [TBL] [Abstract][Full Text] [Related]
15. Antiaggregant and antivasospastic properties of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate. Lardy C; Rousselot C; Chavernac G; Depin JC; Guerrier D Arzneimittelforschung; 1994 Nov; 44(11):1196-202. PubMed ID: 7848331 [TBL] [Abstract][Full Text] [Related]
16. Hypotensive and antiaggregative effects of eugenosedin-B with serotonin and alpha/beta-adrenoceptor antagonistic activities in rats and human platelets. Shen KP; Chu LW; Hsieh SL; An LM; Chen IJ; Wu BN J Cardiovasc Pharmacol; 2008 Feb; 51(2):154-61. PubMed ID: 18287883 [TBL] [Abstract][Full Text] [Related]
17. AHR-16303B, a novel antagonist of 5-HT2 receptors and voltage-sensitive calcium channels. Barrett RJ; Appell KC; Kilpatrick BF; Proakis AG; Nolan JC; Walsh DA J Cardiovasc Pharmacol; 1991 Jan; 17(1):41-53. PubMed ID: 1708055 [TBL] [Abstract][Full Text] [Related]
18. Differential inhibition of 5-hydroxytryptamine (5-HT) mediated contraction of rat thoracic aortae by phentolamine and tolazoline: correlation with inhibition of 5-HT binding and calcium ion. Curro FA; Greenberg S Methods Find Exp Clin Pharmacol; 1983; 5(2):107-20. PubMed ID: 6876942 [TBL] [Abstract][Full Text] [Related]
19. Studies on the pharmacology of the novel histamine H3 receptor agonist Sch 50971. Hey JA; Aslanian R; Bolser DC; Chapman RW; Egan RW; Rizzo CA; Shih NY; Fernandez X; McLeod RL; West R; Kreutner W Arzneimittelforschung; 1998 Sep; 48(9):881-8. PubMed ID: 9793613 [TBL] [Abstract][Full Text] [Related]